Table 1 Baseline and clinical characteristics of the study population
SACT (n = 489) | no-SACT (n = 289) | p | |
|---|---|---|---|
Male | 338 (69.1%) | 219 (75.8%) | 0.049 |
Female | 151 (30.9%) | 70 (24.2%) | |
Age at the time of MDT | < 0.001 | ||
≤ 49.9 | 20 (4.1%) | 5 (1.7%) | |
50–64.9 | 194 (39.7%) | 45 (15.6%) | |
65–74.9 | 183 (37.4%) | 115 (39.8%) | |
≥ 75 | 92 (18.8%) | 124 (42.9%) | |
median (Q25–Q75) | 66 (60–73) | 73 (67–79) | |
Biopsy | |||
Yes | 483 (98.8%) | 222 (76.8%) | < 0.0001 |
No | 6 (1.2%) | 67 (23.2%) | |
Histology | < 0.001 | ||
adenocarcinoma | 168 (34.4%) | 45 (15.6%) | |
squamous | 124 (25.4%) | 69 (23.9%) | |
small cell | 125 (25.6%) | 40 (13.8%) | |
Other/no malignancy/no histology | 72 (14.7%) | 135 (46.7%) | |
Stage | 0.74 | ||
II | 2 (0.4%) | 0 (0%) | |
III | 137 (28.0%) | 80 (27.7%) | |
IV | 350 (71.6%) | 209 (72.3) | |
Newly diagnosed | 390 (79.8%) | 252 (87.2%) | 0.008 |
Recurrence | 99 (20.2%) | 37 (12.8%) | |
Time from biopsy to MDT (days) | |||
median (Q25–Q75) | 12 (2–27) | 8 (0–18) | 0.0005 |
(min–max) | (0–3555) | (0–3240) | |
Palliative radiotherapy | |||
≤ 3 months before MDT | 14 (2.9%) | 6 (2.1%) | 0.64 |
since MDT | 181 (37.0%) | 16 (5.5%) | < 0.001 |
Comorbidities | |||
≤ 3 months before MDT | |||
Sepsis | 1 (0.2%) | 2 (0.7%) | 0.56 |
Bacterial infection | 0 (0%) | 4 (1.4%) | 0.019 |
Drug-related neutropenia | 0 (0%) | 0 (0%) | |
Diabetes | 54 (11.0%) | 42 (14.5%) | 0.176 |
Atrial fibrillation | 49 (10.0%) | 53 (18.3%) | 0.001 |
Cardiovascular disease | 266 (54.4%) | 187 (64.7%) | 0.005 |
COPD | 107 (21.9%) | 85 (29.4%) | .02 |
since MDT | |||
Sepsis | 52 (10.6%) | 16 (5.5%) | 0.018 |
Bacterial infection | 44 (9.0%) | 3 (1.0%) | < 0.001 |
Drug-related neutropenia | 34 (7.0%) | 0 (0%) | < 0.001 |
COPD | 109 (22.3%) | 13 (4.5%) | .001 |